Sphera Healthcare US Inc

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Sphera Healthcare US Inc
CRD #310325
SEC #801-121782
CIK #0001891596
AUM
Employees 6 (67% Investors, 0% Brokers)
Fees
Minimum
Phone212-554-4457
Address10 East 53rd Street
New York, NY 10022
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($M)
100080060040020002009201420192025
Fees and Compensation — Form ADV Part 2A (3/31/2022) [Brochure]
Item 5: Fees and Compensation

The fees applicable to each of the Funds are set forth in detail in the corresponding Offering
Documents. A brief summary of such fees is provided below.

Management Fee

As compensation for investment management services rendered to the Funds, Sphera
Healthcare US is paid an investment management fee (“Management Fee”) per annum based
on the net asset value of the Funds. Management Fees are not paid in advance.

A complete list of share classes issued by the Funds since inception and the corresponding
fees for each class (including the manner and calculation of Management Fees) are detailed
in each Fund’s respective Offering Documents. The Management Fees and other fees
described herein are generally subject to modification, waiver or reduction by Sphera
Healthcare US in its sole discretion, both voluntarily and on a negotiated basis with selected
Investors, which may not be disclosed to other Investors in the same Fund. The fee structures
described herein may be modified from time to time. Fees may differ from one Fund to
another, as well as among Investors in the same Fund.

Certain investors in the Funds that are employees, business associates and other “friends and
family” of the Firm, its affiliates or their personnel (“Sphera Investors”) will not typically pay
Management Fees in connection with their investment in a Fund. Notwithstanding that

Sphera Healthcare US Inc.                                           Form ADV Part 2A Brochure

Sphera Investors will generally not pay Management Fees, Sphera Investors will generally pay
for their pro rata share of certain Fund expenses.

Other Types of Fees or Expenses

The Firm is responsible for and shall pay, or cause to be paid, all of their own ordinary
administrative and overhead expenses, including, without limitation, all costs and expenses
related to rent, furniture, fixtures, office equipment, office supplies, clerical expenses and all
salaries, bonuses and benefits paid to, or on behalf of, personnel of the Firm to the extent set
forth in the Funds’ Offering Documents.

The Funds will pay for all reasonable expenses related to the Funds’ organization, including,
but not limited to, legal and accounting fees, government filing fees and printing and mailing
expenses, syndication expenses, costs and expenses of the preparation of the Funds’ legal
agreements, the Offering Documents, and other documents to be furnished by the Funds or
the Firm to prospective investors and other expenses of the initial offering of Units (as defined
in the Offering Documents) (“Organizational Expenses”).

In addition to the Organizational Expenses described above, the Funds will bear the ongoing
expenses relating to the operation of the Funds (or where necessary and appropriate, the Firm
or the Fund general partner shall be reimbursed by the Funds for any such costs and
expenses). Expenses include, but are not limited to, (i) expenses of the continuing offering of
Units or Interests or Shares (as defined in the Offering Documents) (including, for the
avoidance of doubt, fees and expenses in connection with printing and other expenses
associated with the admission of an Investor, any regulatory filings (such as blue sky filings
and the European Alternative Investment Fund Managers Directive related expenses), but not
including the Firm or Fund general partner’s travel and lodging expenses relating to marketing
the Units or Interests or Shares), (ii) all costs and expenses related to investment and
divestment transactions of the Funds, including costs of examination, sourcing and monitoring
of prospective investments, whether or not consummated (including legal expenses incurred
in connection with claims or disputes related to unconsummated investments and third-party
investment sourcing fees), (iii) any withholding, transfer or other taxes imposed on the Funds
or any of their partners, including without limitation expenses for tax return preparation and
reporting that are not allocated specifically by the Firm or the Fund general partner to and
paid for by a particular Investor, subject, in each case, to the terms of the Offering Documents,
(iv) any governmental and regulatory fees imposed on the Funds, (v) any financing,
commitment, interest and other borrowing costs payable by the Funds and/or other bank
service fees, and all costs and expenses related to the hedging transactions employed by the
Funds, including expenses relating to borrowing securities to be sold short, (vi) litigation and
indemnification expenses and any legal fees and costs (including settlement costs) arising in
connection with any litigation or regulatory investigation instituted against the Funds, the
Firm or the Fund general partner in its capacity as such, (vii) the cost of the audit of the Funds’
financial statements and the preparation of their tax returns and tax compliance, (viii) the fees
and expenses of the Funds’ counsel in connection with advice directly relating to the Funds’
legal affairs, (ix) the costs of “directors and officers” and professional liability insurance and
of professional liability insurance for the Funds, a Fund general partner and their respective
officers, employees, advisers and agents, members of the Advisory Board (as defined in the
Offering Documents) and members of the board of directors of Sphera Global Healthcare GP
Ltd (acting where relevant as the general partner of the general partner of the general partner
of a Fund), (x) fund administrator fees (such as portfolio and investor accounting, tax reporting
and investor servicing cost), and/or the fees of any transfer agent and registrar, (xi) costs

Sphera Healthcare US Inc.                                          Form ADV Part 2A Brochure

incurred in respect of the preparation, audit and distribution of annual and other reports and
accounts, (xii) costs of any outside appraisers (including third-party valuation agents for
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2022) [Brochure]
Item 7: Types of Clients

The Investment Manager’s Clients will be the Funds, as described in Item 4 above, and the
Funds are generally open to, among others, institutions, pension plans, endowments, high
net-worth individuals, financially sophisticated individuals, and other sophisticated investors.
Investment advice will be provided directly to the Funds and not individually to the Investors
in such Funds.

There is no minimum size for a Fund but minimum subscriptions are established for Investors
in the Funds. The minimum initial subscription amount by Investors in the Funds is
US$500,000, subject to Sphera Healthcare’ or the Funds’ general partner’s, as applicable,
discretion to reduce this to not less than US$100,000.

Section 3(c)(7) of the Company Act, is available to a private investment fund that does not
publicly offer its securities and limits its U.S. persons owners to “Qualified Purchasers.” A
Qualified Purchaser is generally defined as any natural person who owns at least $5 million in
investments and any other person (i.e., an institutional investor) that, for its own account or

Sphera Healthcare US Inc.                                          Form ADV Part 2A Brochure

the accounts of other Qualified Purchasers, in the aggregate, owns and invests on a
discretionary basis at least $25 million.

The Investment Manager will rely on the Section 3(c)(7) exemption from the investment
company definition and will offer and sell interests in the relevant Funds only to U.S. persons
who are Qualified Purchasers. In addition, units of the Funds’ will be sold outside the U.S. only
to investors in a private offering, made to a limited number of investors, and provided that
such issuance does not constitute an offer to purchase units that requires a publication of a
prospectus in any jurisdiction. Only investors who meet specific eligibility requirements in
their respective jurisdictions will be able to purchase the Fund’s units.
Sector Form 13F Holdings Value ($M)
Astrazeneca PLC 52.8
Johnson & Johnson 49.1
Lilly Eli & Co 42.9
Sanofi 42.3
Teva Pharmaceutical Industries Ltd 34.1
AbbVie Inc 33.4
Novo Nordisk A S 29.1
Merck & Co Inc 26.0
Syndax Pharmaceuticals Inc 21.9
Pharmathene Inc 16.3
View All
Holdings by Sector ($M)
1500120090060030002013201720222027
Type Form D Funds Date Sold AUM
HF Sphera Biotech Master Fund LP [2019-02-25] 32.1 M 182.2 M
Filed 2025-04-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Sphera Global Healthcare Master Fund [2014-10-21] 607.6 M
Filed 2025-04-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 6 789.8
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 6 789.8
By Discretionary
Discretionary 6 789.8
Non-Discretionary 0 0.0
Total 6 789.8
By Non-United States Persons
Non-United States Persons 756.3
United States Persons 33.5
Total 6 789.8
Form D Directors Role # Filings # Firms 2011 - 2026
Itschak Shrem Director 8 3
Nicola Grenham Director 5 3
Doron Breen Director 5 3
Israel Mor Director 4 3
Menachem Inbar Director 3 2
Nir Arkin Director 3 2
Ori Goldfarb Director 2 2
Yaacov Nir Director 2 2
Hanna Lerman Director 2 2
Adi Hanetz Director 2 2
View All
EDGAR Form CIK 2011 - 2026
13F-NT [0001891596]
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund
LEI254900Z6UO74Z4VJBU45
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com